Concepedia

Xiling Jiang

XJ

Statistics

Publications

11

Citations

615

H-Index

10

Active since

2015

Affiliations

Center for Drug Evaluation and Research(Current)

United States Food and Drug Administration

Janssen (United States)

Center for Devices and Radiological Health

Swarthmore College

Xiling Jiang is an author at Center for Drug Evaluation and Research specializing in pharmacology, pharmacy, and pharmacokinetics.

Publications per year

2015–2023

11

Publications

11

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Sandra J. Casak, Martha Donoghue, Lola A. Fashoyin‐Aje et al. · Clinical Cancer Research · 2020 · 178 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Preeti Narayan, Tatiana M. Prowell, Jennifer Gao et al. · Clinical Cancer Research · 2020 · 166 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents

Xiling Jiang, Xi Chen, Thomas Carpenter et al. · mAbs · 2018 · 60 citations · Full text

Medicine, Immunology, Pharmacology +17

FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer

Jennifer Gao, Christy Osgood, Yutao Gong et al. · Clinical Cancer Research · 2020 · 45 citations

Medicine, Oncology, Pharmacokinetics +17

Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis

Xi Chen, Xiling Jiang, William J. Jusko et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2016 · 35 citations · Full text

Pharmacy, Immunology, Pharmacokinetics +13

1–5 of 11